ELGX Endologix Inc

IRVINE, Calif., Aug. 3, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences.  The first presentation will be at the 31st Annual Canaccord Genuity Growth Conference in Boston, MA.

The second presentation will be at Wedbush Securities 2011 Life Sciences Management Access Conference in New York.

An audio Web cast of the Company's presentations will be available by visiting the investor relations section of Endologix's Web site at www.endologix.com.  A replay of the presentations will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S.  The Nellix® Endovascular System and Ventana™ Fenestrated Stent Graft System are investigational devices.  Additional information can be found on Endologix's Web site at www.endologix.com.

SOURCE Endologix, Inc.